Brian Taylor Slingsby - May 22, 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director, 10%+ Owner
Signature
Brian Taylor Slingsby by: /s/ Adam Levy, Attorney-in-fact
Stock symbol
MLYS
Transactions as of
May 22, 2024
Transactions value $
$0
Form type
4
Date filed
1/7/2025, 05:58 PM
Previous filing
Jul 14, 2023
Next filing
Jul 26, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Other $0 -22K -100% $0.00 0 May 22, 2024 Common Stock 22K $12.52 Direct F1, F2
transaction MLYS Stock Option Other $0 +22K $0.00 22K May 22, 2024 Common Stock 22K $12.52 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.
F2 The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.
F3 Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.